
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is a leading innovator in the field of surgical treatments for cardiovascular diseases, specifically atrial fibrillation and left atrial appendage management. The company's diverse product line and strong sales force make it well-positioned for continued growth in the coming years. The recent 4Q25 results and 2026 guidance showcase the company's potential for double-digit growth and improved profitability. AtriCure also has additional potential opportunities in pain management and minimally invasive procedures, which could further drive revenue and margin expansion. With a low EV/revenue multiple and multiple potential growth drivers, AtriCure has a positive outlook for durable revenue growth and improved profitability.
Bears say
AtriCure is facing multiple challenges, including declining sales in its minimally invasive ablation platform and reimbursement pressure in its fastest growing European market, which are expected to continue in 2026. While the company has promising clinical trials and potential for improved sales and margins, these factors are currently overshadowed by the challenges and do not provide enough confidence for a positive outlook.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares